|
2025
|
P/S
|
Therapeutic agents for the diagnosis, treatment and
prevention of diseases and disorders, namely... |
|
|
P/S
|
Therapeutic agents for the diagnosis, treatment and prevention of diseases and disorders, namely,... |
|
|
P/S
|
Monoclonal antibodies for medical purposes; pharmaceutical preparations, namely, antibodies for t... |
|
|
P/S
|
patient and caregiver support services and medical information relating to spinal muscular atroph... |
|
|
Invention
|
Myostatin-selective inhibitors for treating metabolic disorders. Disclosed herein are therapeutic... |
|
|
P/S
|
Monoclonal antibodies for medical purposes; antibodies for the treatment of spinal muscular atrop... |
|
|
Invention
|
Tgf-beta inhibitors for treating cancer. The present disclosure provides TGFβ inhibitor therapy f... |
|
|
Invention
|
Rgmc-selective inhibitors and use thereof.
Selective inhibitors of repulsive guidance molecule C... |
|
|
Invention
|
High-affinity, isoform-selective tgfß1 inhibitors and use thereof.
Disclosed herein are monoclon... |
|
|
P/S
|
therapeutic agents for the diagnosis, treatment and prevention of diseases and disorders, namely,... |
|
2024
|
Invention
|
Selective and potent inhibitory antibodies of myostatin activation. The present disclosure relate... |
|
|
Invention
|
Ltbp complex-specific inhibitors of tgfb and uses thereof.
Disclosed herein are inhibitors, such... |
|
|
Invention
|
Isoform-selective tgfb1 inhibitors and use thereof.
Disclosed herein are monoclonal antibodies a... |
|
|
Invention
|
Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies... |
|
|
Invention
|
Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients. The presen... |
|
|
Invention
|
Anti-pro/latent-myostatin antibodies and uses thereof.
Aspects of the present disclosure relate ... |
|
2023
|
Invention
|
Compositions and methods for growth factor modulation. Provided herein are proteins, antibodies, ... |
|
|
Invention
|
Isoform-specific, context-permissive tgfb1 inhibitors and use thereof.
Disclosed herein are ther... |
|
|
Invention
|
Use of myostatin inhibitor for treating spinal muscular atrophy.
Administration of apitegromab l... |
|
|
Invention
|
Use of myostatin inhibitor for treating spinal muscular atrophy. Administration of apitegromab le... |
|
|
P/S
|
Monoclonal antibodies for medical purposes; antibodies for
the treatment of spinal muscular atro... |
|
|
Invention
|
Tgfbeta1-binding immunoglobulins and use thereof.
Disclosed herein are immunoglobulins, such as ... |
|
2022
|
Invention
|
Ltbp complex-specific inhibitors of tgfb1 and uses thereof.
The invention provides method of tre... |
|
|
Invention
|
Ltbp complex-specific inhibitors of tgfβ1 and uses thereof. The invention provides method of trea... |
|
|
Invention
|
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating m... |
|
|
Invention
|
Tgf-beta inhibitors and therapeutic use thereof.
The present disclosure provides TGFβ inhibitor ... |
|
|
Invention
|
Tgf-beta inhibitors and therapeutic use thereof. The present disclosure provides TGFβ inhibitor t... |
|
|
Invention
|
Ltbp complex-specific inhibitors of tgfβ and uses thereof. Disclosed herein are inhibitors, such ... |
|
|
Invention
|
Tgf-beta inhibitors and use thereof.
The present disclosure provides TGFβ inhibitor therapy for ... |
|
|
Invention
|
Tgf-beta inhibitors and use thereof. The present disclosure provides TGFβ inhibitor therapy for t... |
|
2021
|
Invention
|
Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy.
The present disc... |
|
|
Invention
|
Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy. The present discl... |
|
|
Invention
|
Methods for treating metabolic diseases by inhibiting myostatin activation.
The present inventio... |
|
|
Invention
|
Compositions for making and using anti-myostatin antibodies. Aspects of the present disclosure re... |
|
|
Invention
|
Isoform-selective tgfb1 inhibitors and use thereof. Disclosed herein are monoclonal antibodies an... |
|
|
Invention
|
Tgfβ antibodies, methods and uses. ProTGFβ1-GARP complex-selective antibodies, polynucleotides ca... |
|
|
Invention
|
Use of myostatin inhibitors and combination therapies.
The present disclosure relates to the tre... |
|
|
Invention
|
Tgfb inhibitors and use thereof.
Disclosed herein are novel inhibitors of TGFβ1 activation with ... |
|
|
Invention
|
Tgfβ inhibitors and use thereof. Disclosed herein are novel inhibitors of TGFβ1 activation with d... |
|
|
Invention
|
Tgf-beta inhibitors and use thereof. The present disclosure provides TGFp inhibitor therapy for t... |
|
2020
|
Invention
|
Methods for altering body composition by administering anti-pro/latent myostatin antibodies. The ... |
|
|
Invention
|
Methods for using anti-myostatin antibodies. Aspects of the present disclosure relate to antibodi... |
|
|
Invention
|
Compositions and methods for growth factor modulation.
Provided herein are proteins, antibodies,... |
|
2019
|
Invention
|
Rgmc-selective inhibitors and use thereof. Selective inhibitors of repulsive guidance molecule C ... |
|
|
Invention
|
Tgfß1 inhibitors and use thereof.
Disclosed herein are monoclonal antibodies and antigen-binding... |
|
|
Invention
|
Methods of screening for high-affinity, isoform-selective tgfβ1 inhibitors. Disclosed herein are ... |
|
2018
|
Invention
|
Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof. Disclosed herein are inhibitors,... |
|
|
Invention
|
Lrrc33 inhibitors and use thereof.
Disclosed herein are LRRC33 inhibiting agents and related met... |
|
2012
|
P/S
|
Research and development in the pharmaceutical and biotechnology fields; pharmaceutical research ... |
